MarketScreener Homepage > Equities > NASDAQ OMX STOCKHOLM > Probi AB (publ) PROB SE0001280355

Report

Delayed NASDAQ OMX STOCKHOLM - 01/22 11:29:39 am
483	SEK		+0.21%

01/15

PROBI : Truths, Facts and Why Probiotics Matter (IPA webinar for media)

2020

Q3 2020 : Strong growth with good profitability

2020

PROBI : acquires shares in Vital Nutrients Holdings and enters into strategic partnership

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq Omx Stockholm

01/18/2021	01/19/2021	01/20/2021	01/21/2021	01/22/2021	Date
471(c)	471.5(c)	473.5(c)	482(c)	483(c)	Last
3 354	1 960	2 792	3 400	3 383	Volume
+0.64%	+0.11%	+0.42%	+1.80%	+0.21%	Change

More quotes

Financials

Sales 2020	711 M 85,8 M 85,8 M
Net income 2020	102 M 12,2 M 12,2 M
Net cash position 2020	259 M 31,3 M 31,3 M
P/E ratio 2020	54,3x
Yield 2020	0,32%

Sales 2021	758 M 91,4 M 91,4 M
Net income 2021	117 M 14,1 M 14,1 M
Net cash position 2021	360 M 43,4 M 43,4 M
P/E ratio 2021	46,7x
Yield 2021	0,45%

Capitalization	5 503 M 664 M 664 M
EV / Sales 2020	7,38x
EV / Sales 2021	6,79x
Nbr of Employees	-
Free-Float	39,3%

More Financials

Company

Probi AB is a Sweden-based company engaged in the probiotics research and development. The Companyâ€™s activities are divided into two business areas: Functional Foods, which focuses on the probiotics application in food in partnership with food companies; and Consumer Healthcares, which develops, commercializes and sells Probi probiotics in collaboration with a range of entities, such as pharmaceutical companies...

Sector

Food Processing

Calendar

02/09

Earnings Release

More about the company

Notations Surperformance© of Probi AB (publ)

Trading Rating :

Investor Rating :

More Ratings

All news about PROBI AB (PUBL)

01/15	PROBI : Truths, Facts and Why Probiotics Matter (IPA webinar for media)	AQ
2020	Q3 2020 : Strong growth with good profitability	AQ
2020	PROBI : acquires shares in Vital Nutrients Holdings and enters into strategic pa..	AQ
2020	PROBI : Presentation of Probi's Q3 report	AQ
2020	PROBI : New clinical results on stress from Probi and their probiotic strain L. ..	AQ
2020	Q2 2020 : Probi raises long-term financial targets	AQ
2020	PROBI PUBL : Presentation of Probi's Q2 report 2020 and new financial targets	PU
2020	PROBI PUBL : Presentation of Probi's Q2 report 2020 and new financial targets	AQ
2020	PROBI PUBL : and Örebro University to collaborate on research into exploration o..	AQ
2020	PROBI PUBL : A true pioneer in probiotic research is elected NutraChampion 2020	AQ
2020	PROBI AB (PUBL) : Ex-dividend day for final dividend	FA
2020	PROBI PUBL : ´s Annual General Meeting 2020	PU
2020	PROBI PUBL : Annual General Meeting 2020	AQ
2020	Q1 2020 : A solid start to the year	AQ
2020	PROBI PUBL : Presentation of Probi's Q1 report 2020	PU

More news

News in other languages on PROBI AB (PUBL)

2020	PROBI AB (PUBL) : rentabilité renforcée
2018	PROBI AB : Veröffentlichung des Halbjahresergebnisses
2018	PROBI AB : publication des résultats semestriels
2018	PROBI AB : Veröffentlichung des Jahresergebnisses
2018	PROBI AB : publication des résultats annuels

More news

Analyst Recommendations on PROBI AB (PUBL)

2014

No appetite for big consumer goods? Try their suppliers

More recommendations

Provided by Scoopnest.com

Chart PROBI AB (PUBL)

Duration : Period :

Probi AB (publ) Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends PROBI AB (PUBL)

	Short Term	Mid-Term	Long Term
Trends	Bullish	Bullish	Bullish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Mean consensus	-
Number of Analysts	2
Average target price	440,00 SEK
Last Close Price	483,00 SEK
Spread / Highest target	-8,90%
Spread / Average Target	-8,90%
Spread / Lowest Target	-8,90%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Tom Juhani Rönnlund	Chief Executive Officer
Jean-Yves Parisot	Chairman
Andy McShea	Vice President-Operations
Henrik Lundkvist	Chief Financial Officer
Niklas Brandt	Vice President-Information Technology

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

PROBI AB (PUBL)	14.46%	664



BY-HEALTH CO., LTD.	7.62%	6 340
BALCHEM CORPORATION	2.27%	3 812
THE SIMPLY GOOD FOODS COMPANY	-12.63%	2 623
MEDIFAST, INC.	12.72%	2 588
BIOGAIA AB (PUBL)	-5.77%	1 233

More Results